Pfizer-BioNTech COVID vaccine remains effective in preventing hospitalizations, find studies


Adult hospitalizations from omicron-related SARS-CoV-2 (COVID-19) were less severe than delta and the Pfizer-BioNTech vaccine (also known as Comirnaty and BNT162b2) remains effective in preventing not only hospitalization, but severe patient outcomes associated with COVID-19, two new research studies have found.

Driver of cystic fibrosis lung inflammation yields target for treatment

Previous article

Economist finds soda taxes aren’t as regressive as previously feared and are effective

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations